← Alnylam Pharmaceuticals, Inc. (ALNY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Alnylam Pharmaceuticals, Inc. (ALNY)
Pharmaceutical Preparations · market cap $33.2B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
20
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Alnylam Pharmaceuticals (ALNY) is a Cambridge-based RNAi therapeutics pioneer with a $42.65B market cap and a commercially validated platform anchored by Amvuttra (vutrisiran, approved for hATTR amyloidosis with polyneuropathy). The company turned profitable in 2025 with $314M net income on $3.71B in revenue, and carries a net cash position of approximately $701M. Key near-term focus is vutrisiran's Phase 3 readout for ATTR cardiomyopathy (ATTRCm), the much larger indication, alongside a maturing pipeline spanning hypertension, Alzheimer's, obesity, and rare diseases.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2027-04-27 (est.)Phase 2 · ALN-2232imp 7/10
- 2027-08-31 (est.)Phase 2 · ALN-4324imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Amvuttra | Approved | hATTR Amyloidosis |
| ALN-APP | Phase 2 | Alzheimer Disease |
| Vutrisiran | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy |
| ALN-2232 | Phase 2 | Obesity |
| ALN-AGT01 RVR | Phase 2 | Hypertension |
| Mivelsiran | Phase 2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) |
| ALN-CC5 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Lumasiran | Phase 3 | PH1 |
| ALN-TTR02 (patisiran) administered by intravenous (IV) infusion | Phase 2 | TTR-mediated Amyloidosis |
| ALN-4324 | Phase 2 | Obese or Overweight Healthy Volunteers |
| ALN-TTRSC (revusiran) for subcutaneous administration | Phase 2 | TTR-mediated Amyloidosis |
| Zilebesiran | Phase 3 | Hypertension |
| ALN-RSV01 | Phase 2 | Respiratory Syncytial Virus Infections |
| Nucresiran | Phase 3 | Transthyretin Amyloidosis With Cardiomyopathy |
| patisiran (ALN-TTR02) | Phase 3 | TTR-mediated Amyloidosis |
| ALN-AGT01 | Phase 2 | Hypertension |
| Givosiran | Phase 3 | Acute Hepatic Porphyria |
| Patisiran | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy |
| ALN-6400 | Phase 2 | Hereditary Hemorrhagic Telangiectasia |
| Revusiran (ALN-TTRSC) | Phase 3 | TTR-mediated Amyloidosis |
Price & technical context
3-month
-18.2%
6-month
-25.4%
12-month
-45.9%
52-wk range
$205.48–$491.22
vs 50-day MA
+1.5%
vs 200-day MA
-19.0%
Realized vol
50.4%
Max drawdown
-58.2%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALNY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.